A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2B Trial to Evaluate the Safety and Efficacy of BMS-823778 in Overweight and Obese Subjects With Inadequately Controlled Hypertension.
Latest Information Update: 24 Dec 2021
At a glance
- Drugs BMS 823778 (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- 23 Aug 2013 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 28 Mar 2013 Planned End Date changed from 1 Apr 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 01 Feb 2013 Planned End Date changed from 1 Jul 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.